Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast Cancer

Next Previous
Trial Profile

A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Paclitaxel
  • Indications Early breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms APPALACHES

    • Most Recent Events

    • 23 Jul 2019 Planned End Date changed from 7 May 2031 to 13 Jun 2031.
    • 23 Jul 2019 Planned primary completion date changed from 7 May 2024 to 13 Jun 2024.
    • 20 Jun 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top